Listed below are brief updates on several recent policy developments across the country. Read more...

On May 24, 2021 the New York Workers’ Compensation Board (WCB) announced a delay of OnBoard-Limited Release via bulletin 046-1408. Read more...

Listed below are brief updates on several recent policy developments across the country. Read more...

The U.S. Food and Drug Administration (FDA) approved a higher-dose naloxone hydrochloride nasal spray – Kloxxado™ (8 mg) – on April 30, 2021. Naloxone is indicated for the emergency treatment of known or suspected opioid analgesic overdose, as manifested by respiratory and/or central nervous system (CNS) depression, for adults and pediatric patients. Read more...

Pregabalin extended-release (ER) tablets, the generic formulation of Lyrica® CR, was released on April 13, 2021, according to the U.S. Food and Drug Administration (FDA). Read more...

The Centers for Medicare and Medicaid Services (CMS) released Version 3.3 of the Workers’ Compensation Medicare Set-Aside Arrangement (WCMSA) Reference Guide, which clarifies how to calculate the seed money (initial deposit) in a structured WCMSA. Read more...

When injured persons receive physical therapy early in the claim, multiple industry data sources show use of opioids and other pain medications and surgeries are reduced along with time away from work. Read more...

The generic formulation of Hysingla® ER, hydrocodone bitartrate extended-release (ER) tablets, was released in March 2021 according to the U.S. Food and Drug Administration (FDA). Hysingla ER is FDA-approved for the treatment of severe pain in patients who require daily, around-the-clock, long-term opioid analgesic treatment. Read more...